医学
内科学
肿瘤科
无容量
化疗
克拉斯
优势比
肺癌
癌症
免疫疗法
结直肠癌
作者
Andrew J. Armstrong,Hilary Dietz,David Balli,William J. Geese,Chunzhe Duan,Yu-Han Hung,Virginia Ip,Gerald Li,Ryon P. Graf,Neal Ready
标识
DOI:10.1158/1078-0432.ccr-25-0952
摘要
LRP1b mutations are a candidate predictive biomarker for immune checkpoint inhibition versus chemotherapy in NSCLC. Further mechanistic characterization of LRP1b and prospective validation are warranted and might enable future clinical use.
科研通智能强力驱动
Strongly Powered by AbleSci AI